|Bid||56.96 x 800|
|Ask||111.18 x 900|
|Day's Range||94.48 - 95.24|
|52 Week Range||79.20 - 121.98|
|Beta (3Y Monthly)||1.64|
|PE Ratio (TTM)||40.72|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.00|
PRA Health Sciences, Inc. (NASDAQ:PRAH), which is in the life sciences business, and is based in United States, saw a decent share price growth in the teens level on the NASDAQGS over the las...
RALEIGH, N.C., April 09, 2019 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2019 results after the market closes on Wednesday, May 1, 2019. The.
PRA Health Sciences Inc NASDAQ/NGS:PRAHView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for PRAH with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PRAH are favorable with net inflows of $72.33 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
RALEIGH, N.C., April 08, 2019 -- PRA Health Sciences, Inc. is pleased to announce it has won a 2019 CRO Leadership Award in the following categories: Capabilities.
Medical technology stocks hit record highs last year and are spiking in 2019. Four of the fastest growing among them have tacked on double-digit earnings growth for several years.
PRA Health Sciences (PRAH) could produce exceptional returns because of its solid growth attributes.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! PRA Health Sciences, Inc.'s (NASDAQ:PRAH) latest earnings update in DecemberRead More...
The best employers around the country are annually recognized for their commitment to developing and sustaining a culture that supports, promotes, and values its employees with the Top Workplaces Award. This year, Philadelphia Inquirer partnered with Energage, a research company that administers online surveys to employees, to honor the companies nominated in the Greater Philadelphia area. “We’re thrilled to once again be recognized as a Top Workplace,” said Samir Shah, President of Strategic Solutions.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll show how PRA Health Sciences, Inc.'s (NASDAQ:PRAH)Read More...
Net new business of $667.3 million in the fourth quarter; Net book-to-bill of 1.30$729.6 million of revenue in the fourth quarter; 11.2% growth at actual foreign exchange rates.
PRA Health Sciences and the non-profit Center for Information and Study on Clinical Research Participation (CISCRP) are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers. A key focus for PRA is to provide a more positive overall experience for both patients and families throughout the clinical trial process. Trial Results Summaries — also called lay language summaries or plain language summaries — communicate the results of clinical trials in a format and layout that is easy to understand and accessible to patients and the public.
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.